PT2988780T - Polipeptídeos f de pré-fusão do rsv solúveis estabilizados - Google Patents

Polipeptídeos f de pré-fusão do rsv solúveis estabilizados

Info

Publication number
PT2988780T
PT2988780T PT14719022T PT14719022T PT2988780T PT 2988780 T PT2988780 T PT 2988780T PT 14719022 T PT14719022 T PT 14719022T PT 14719022 T PT14719022 T PT 14719022T PT 2988780 T PT2988780 T PT 2988780T
Authority
PT
Portugal
Prior art keywords
polypeptides
stabilized soluble
prefusion rsv
soluble prefusion
rsv
Prior art date
Application number
PT14719022T
Other languages
English (en)
Inventor
Petrus Maria Langedijk Johannes
Krarup Anders
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326107&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2988780(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of PT2988780T publication Critical patent/PT2988780T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT14719022T 2013-04-25 2014-04-24 Polipeptídeos f de pré-fusão do rsv solúveis estabilizados PT2988780T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13165402 2013-04-25

Publications (1)

Publication Number Publication Date
PT2988780T true PT2988780T (pt) 2019-03-25

Family

ID=48326107

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14719022T PT2988780T (pt) 2013-04-25 2014-04-24 Polipeptídeos f de pré-fusão do rsv solúveis estabilizados

Country Status (33)

Country Link
US (3) US10899800B2 (pt)
EP (2) EP2988780B1 (pt)
JP (1) JP6469081B2 (pt)
KR (1) KR102236497B1 (pt)
CN (2) CN105188745B (pt)
AP (1) AP2015008815A0 (pt)
AR (1) AR096113A1 (pt)
AU (1) AU2014259474B2 (pt)
CA (1) CA2910067C (pt)
CL (1) CL2015003124A1 (pt)
CY (1) CY1121600T1 (pt)
DK (1) DK2988780T3 (pt)
EA (2) EA035522B1 (pt)
ES (1) ES2715378T3 (pt)
HK (1) HK1220124A1 (pt)
HR (1) HRP20190175T1 (pt)
HU (1) HUE041659T2 (pt)
IL (1) IL242186B (pt)
LT (1) LT2988780T (pt)
ME (1) ME03442B (pt)
MX (1) MX361774B (pt)
MY (2) MY181066A (pt)
PE (1) PE20151867A1 (pt)
PH (1) PH12015502377B1 (pt)
PL (1) PL2988780T3 (pt)
PT (1) PT2988780T (pt)
RS (1) RS58436B1 (pt)
SG (1) SG11201508567XA (pt)
SI (1) SI2988780T1 (pt)
TR (1) TR201902513T4 (pt)
TW (1) TWI663175B (pt)
WO (1) WO2014174018A1 (pt)
ZA (1) ZA201507912B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
ES2582005T3 (es) 2008-12-09 2016-09-08 Novavax, Inc. Proteínas F del RSV modificadas y métodos de su uso
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
AU2014243756B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2988780B1 (en) 2013-04-25 2018-12-26 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2016160166A1 (en) * 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
PL3319633T3 (pl) * 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
US10538557B2 (en) 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
EA202092251A1 (ru) * 2016-02-03 2020-12-11 Янссен Сайенсиз Айрлэнд Юси Комбинированные продукты для лечения rsv
AU2017242020B2 (en) 2016-03-29 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
WO2017174568A1 (en) * 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
MX2018012095A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
DK3464331T3 (da) * 2016-05-30 2021-01-18 Janssen Vaccines & Prevention Bv Stabiliserede præfusions-rsv f-proteiner
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
SG11201908999QA (en) 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
JP2020519663A (ja) * 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
EP3681533A1 (en) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
BR112020019108A2 (pt) 2018-03-19 2020-12-29 Novavax, Inc. Vacinas polivalentes de nanopartículas de influenza
US20210401969A1 (en) * 2018-10-29 2021-12-30 Emory University Rsv virus-like particles and methods of use thereof
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
CN109851678A (zh) * 2019-03-07 2019-06-07 苏州宇之波生物科技有限公司 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CN113950333A (zh) 2019-05-15 2022-01-18 扬森疫苗与预防公司 使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
KR20220164543A (ko) 2020-04-02 2022-12-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 백신 조성물
BR112022026408A2 (pt) 2020-06-29 2023-01-17 Janssen Vaccines & Prevention Bv Combinação vacinal contra infecção pelo vírus sincicial respiratório
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN114195867B (zh) * 2021-12-15 2024-05-03 北京交通大学 一种rsv融合前f蛋白、表达质粒、细胞株和rsv疫苗组合物
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024067725A1 (zh) * 2022-09-29 2024-04-04 北京百邑无忧科技发展有限公司 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
CN116785421B (zh) * 2023-08-21 2024-01-09 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种牛呼吸道合胞体病毒的mRNA疫苗及其应用
CN117586357A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
KR100449181B1 (ko) 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int ADENOVIRUS E1-COMPLEMENTING CELL LINES
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
WO1999041416A2 (en) 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE421337T1 (de) 1998-11-16 2009-02-15 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
KR100741247B1 (ko) 1999-05-17 2007-07-19 크루셀 홀란드 비.브이. 아데노바이러스 타입 35의 적어도 하나의 구성성분을포함하는 아데노바이러스 유래 유전자 전달체
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU4346101A (en) 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
JP2004519204A (ja) 2000-05-08 2004-07-02 ダビスコ フーズ インターナショナル インコーポレーテッド 抗高血圧ペプチドの生成のための乳漿タンパク質の酵素処理、得られた産物、および哺乳動物における高血圧の処置
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
CN1617745A (zh) 2002-01-18 2005-05-18 舍林股份公司 稳定的腺病毒配方
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
DK1497438T3 (da) 2002-04-25 2010-01-04 Crucell Holland Bv Midler og fremgangsmåder til fremstilling af adenovirusvektorer
PL208588B1 (pl) 2002-04-25 2011-05-31 Crucell Holland Bv Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
DE60313451T2 (de) 2002-05-14 2008-01-03 Merck & Co., Inc. Verfahren zur reinigung von adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
PL2163260T3 (pl) 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
ES2317517T5 (es) 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
EP4219566A3 (en) * 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
WO2010014975A2 (en) 2008-08-01 2010-02-04 Academia Sinica Use of microrna signatures for assessing risk levels of neuroblastoma patients
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
RU2585227C2 (ru) * 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
KR101778317B1 (ko) 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. 사람 호흡기 세포융합 바이러스(ｒｓｖ)에 대한 항체 및 이용 방법
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
PL2488636T3 (pl) 2009-10-15 2014-07-31 Crucell Holland Bv Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
ES2578514T3 (es) 2010-02-15 2016-07-27 Crucell Holland B.V. Método para la producción de vectores adenovíricos
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
SG194755A1 (en) * 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
NZ628385A (en) 2012-03-12 2016-09-30 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
NZ630649A (en) 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
JP2013247240A (ja) 2012-05-25 2013-12-09 Gigaphoton Inc レーザ装置
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
AU2014243756B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EA035846B1 (ru) 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
WO2014170257A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g protein
EP2988780B1 (en) 2013-04-25 2018-12-26 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion rsv f polypeptides
CN105408348B (zh) * 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US10125172B2 (en) 2013-07-25 2018-11-13 Calder Biosciences Inc. Conformationally stabilized RSV pre-fusion F proteins
HUE041791T2 (hu) 2013-09-19 2019-05-28 Janssen Vaccines & Prevention Bv Javított adenovírus-készítmények
MX2018012095A (es) * 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
WO2017174568A1 (en) * 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins

Also Published As

Publication number Publication date
AU2014259474A1 (en) 2015-11-05
DK2988780T3 (en) 2019-04-08
AP2015008815A0 (en) 2015-10-31
PL2988780T3 (pl) 2019-06-28
TWI663175B (zh) 2019-06-21
NZ713371A (en) 2021-02-26
EP2988780A1 (en) 2016-03-02
EP3488864A1 (en) 2019-05-29
IL242186B (en) 2020-07-30
ME03442B (me) 2020-01-20
AR096113A1 (es) 2015-12-09
SI2988780T1 (sl) 2019-05-31
CY1121600T1 (el) 2020-05-29
EA202090675A2 (ru) 2020-06-30
ZA201507912B (en) 2022-03-30
PE20151867A1 (es) 2016-01-07
WO2014174018A1 (en) 2014-10-30
TR201902513T4 (tr) 2019-03-21
PH12015502377A1 (en) 2016-02-22
EA039803B1 (ru) 2022-03-15
US20230265127A1 (en) 2023-08-24
KR20160002938A (ko) 2016-01-08
PH12015502377B1 (en) 2016-02-22
LT2988780T (lt) 2019-03-12
KR102236497B1 (ko) 2021-04-06
MY201791A (en) 2024-03-18
JP6469081B2 (ja) 2019-02-13
MX361774B (es) 2018-12-17
AU2014259474B2 (en) 2018-09-13
SG11201508567XA (en) 2015-11-27
TW201520221A (zh) 2015-06-01
US10899800B2 (en) 2021-01-26
EP2988780B1 (en) 2018-12-26
MY181066A (en) 2020-12-17
HUE041659T2 (hu) 2019-05-28
CN105188745A (zh) 2015-12-23
CN105188745B (zh) 2019-10-18
EA035522B1 (ru) 2020-06-29
US20210101940A1 (en) 2021-04-08
HK1220124A1 (zh) 2017-04-28
EA202090675A3 (ru) 2020-08-31
MX2015014890A (es) 2016-03-09
RS58436B1 (sr) 2019-04-30
CA2910067C (en) 2023-10-17
US20160102123A1 (en) 2016-04-14
CN110590916A (zh) 2019-12-20
HRP20190175T1 (hr) 2019-03-22
JP2016520039A (ja) 2016-07-11
EA201592048A1 (ru) 2016-04-29
ES2715378T3 (es) 2019-06-04
CL2015003124A1 (es) 2016-05-13
CA2910067A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
HRP20190175T1 (hr) Stabilizirani topljivi prefuzijski rsv f polipeptidi
HK1223949A1 (zh) 穩定的可溶性預融合 多肽
HK1252317A1 (zh) 新的氨基嘧啶衍生物
GB201401167D0 (en) Position sensor
GB201301543D0 (en) Sensor
GB201306097D0 (en) Sensor
AP2015008892A0 (en) Stabilized soluble pre-fusion rsv f polypeptides
GB201314490D0 (en) Position Sensor
GB201305210D0 (en) Component sensor
GB201321388D0 (en) Sensor
GB201311400D0 (en) Position Sensor
GB201313025D0 (en) Sensor